文献速递病毒性肝炎医院感染防控

血液透析患者接受三倍剂量与标准剂量4剂乙型肝炎疫苗接种方案诱导的免疫原性、安全性和持久性

Immunogenicity, Safety, and Persistence Induced by Triple- and Standard-Strength 4-Dose Hepatitis B Vaccination Regimens in Patients Receiving Hemodialysis.
PubMed 文献 · J Infect Dis · 2025-01-01

这项多中心随机平行对照试验纳入504例血液透析患者,随机分为3组:IM20×3组(0、1、6月接种20μg)、IM20×4组(0、1、2、6月接种20μg)、IM60×4组(0、1、2、6月接种60μg)。疫苗诱导抗体应答在7月达峰,随访至30月时三组抗-HBs应答率均下降;IM60×4组维持75%患者保护性抗体的持续时间为29.2月,较IM20×3组的21.0月延长(P=.034)。所有不良反应均为轻度。

要点

  • 疫苗诱导抗体应答在7月达峰,随访7至30月三组抗-HBs应答率均下降。
  • IM60×4组维持75%患者保护性抗体的持续时间为29.2月,较IM20×3组的21.0月延长(P=.034)。
  • IM20×4组持续时间为25.7月,与IM20×3组比较P=.056。

核心结论

  • 三倍剂量4剂乙型肝炎疫苗接种方案可增强血液透析患者的免疫原性和2年持久性。

研究设计与样本

  • 多中心、随机、平行对照试验,于2020年7月至2023年2月在中国山西省11家医院开展,共纳入504例血液透析患者。
  • 参与者按1:1:1随机分配至IM20×3组(0、1、6月接种20μg)、IM20×4组(0、1、2、6月接种20μg)或IM60×4组(0、1、2、6月接种60μg)。

主要发现

  • 疫苗诱导抗体应答在7月达峰。
  • 随访7至30月,抗-HBs应答率在IM20×3组从85.9%(134/156)降至33.0%(33/100),在IM20×4组从92.5%(135/146)降至53.9%(56/104),在IM60×4组从95.4%(145/152)降至57.3%(55/96)。
  • 维持75%患者保护性抗体的疫苗诱导应答持续时间在IM20×3组为21.0月,IM20×4组为25.7月(vs IM20×3组,P=.056),IM60×4组为29.2月(vs IM20×3组,P=.034)。
  • 所有不良反应均为轻度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients receiving hemodialysis represent a high-risk group for hepatitis B virus (HBV) infection. It is crucial to administer hepatitis B vaccination and stimulate higher and more sustained levels of hepatitis B surface antibodies (anti -HBs). Our aim is to enhance the immunogenicity and persistence by implementing high-dose and prolonged hepatitis B vaccine schedules in patients receiving hemodialysis. METHODS: We conducted this multicenter, randomized, parallel-controlled trial between July 2020 and February 2023 at 11 hospitals in Shanxi province, China. A total of 504 patients receiving hemodialysis were enrolled. All participants were randomly allocated in a ratio of 1:1:1 to receive recombinant HBV vaccine of 3 standard doses (20 μg) at 0, 1, and 6 months (IM20 × 3 group), 4 standard doses at 0, 1, 2, and 6 months (IM20 × 4 group), or 4 triple doses (60 μg) at 0, 1, 2, and 6 months (IM60 × 4 group). RESULTS: The vaccine-elicited antibody response peaked at month 7. The follow-up from month 7 to 30 revealed that response rates of anti-HBs decreased from 85.9% (134/156) to 33.0% (33/100) in IM20 × 3 group, from 92.5% (135/146) to 53.9% (56/104) in IM20 × 4 group, and from 95.4% (145/152) to 57.3% (55/96) in IM60 × 4 group. The duration of vaccine-induced response with 75% of patients maintained protective antibodies were 21.0 months in IM20 × 3 group, 25.7 months in IM20 × 4 group (vs IM20 × 3 group, P = .056), and 29.2 months in IM60 × 4 group (vs IM20 × 3 group, P = .034). All the adverse reactions were mild. CONCLUSIONS: The triple-strength 4-dose hepatitis B vaccination regimens could enhance the immunogenicity and 2-year duration in patients receiving hemodialysis.Clinical Trials Registration. NCT03962881.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Yao T, Li Y, Zhang Y, et al. Immunogenicity, Safety, and Persistence Induced by Triple- and Standard-Strength 4-Dose Hepatitis B Vaccination Regimens in Patients Receiving Hemodialysis. J Infect Dis. 2025. PMID: 39378326. doi:10.1093/infdis/jiae494

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。